SELECT * FROM `stock_list` where symbol='AB3A' AND exchange = 'FRA' limit 0,1
SELECT * FROM `stock_list` where symbol='AB3A' AND exchange = 'FRA' limit 0,1
SELECT * FROM `stock_list` WHERE `symbol` = "AB3A" and stock_list.exchange IN (SELECT exchange FROM gurufocu_main.stock_list_exchanges where country='USA' and active=1) limit 0,1 Sarepta Therapeutics (FRA:AB3A) Other Current Liabilities
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sarepta Therapeutics Inc (FRA:AB3A) » Definitions » Other Current Liabilities

Sarepta Therapeutics (FRA:AB3A) Other Current Liabilities : €164 Mil (As of Dec. 2023)


View and export this data going back to 1997. Start your Free Trial

What is Sarepta Therapeutics Other Current Liabilities?

Sarepta Therapeutics's other current liabilities for the quarter that ended in Dec. 2023 was €164 Mil.

Sarepta Therapeutics's quarterly other current liabilities increased from Jun. 2023 (€131 Mil) to Sep. 2023 (€145 Mil) and increased from Sep. 2023 (€145 Mil) to Dec. 2023 (€164 Mil).

Sarepta Therapeutics's annual other current liabilities increased from Dec. 2021 (€98 Mil) to Dec. 2022 (€127 Mil) and increased from Dec. 2022 (€127 Mil) to Dec. 2023 (€164 Mil).

Sarepta Therapeutics Other Current Liabilities Historical Data

The historical data trend for Sarepta Therapeutics's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sarepta Therapeutics Other Current Liabilities Chart

Sarepta Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Sarepta Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Sarepta Therapeutics Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

Sarepta Therapeutics Other Current Liabilities Related Terms

Thank you for viewing the detailed overview of Sarepta Therapeutics's Other Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Sarepta Therapeutics (FRA:AB3A) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sarepta Therapeutics Inc (FRA:AB3A) » Definitions » Other Current Liabilities
Comparable Companies
RPRX INCY UTHR TECH BMRN ROIV LEGN VKTX CERE ASND OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX BNTX
Traded in Other Exchanges
SRPT:USA AB3A:Germany S1RP34:Brazil
Address
215 First Street, Suite 415, Cambridge, MA, USA, 02142
Website
https://www.sarepta.com
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of Sarepta's product candidates are at an early stage of development.

Sarepta Therapeutics (FRA:AB3A) Headlines

No Headlines